F&V Capital Management LLC Takes Position in Bristol-Myers Squibb Co (NYSE:BMY)

Share on StockTwits

F&V Capital Management LLC bought a new stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 3,429 shares of the biopharmaceutical company’s stock, valued at approximately $220,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nuveen Asset Management LLC boosted its holdings in Bristol-Myers Squibb by 14,860.1% during the 2nd quarter. Nuveen Asset Management LLC now owns 9,395,120 shares of the biopharmaceutical company’s stock valued at $426,069,000 after acquiring an additional 9,332,319 shares during the period. BlackRock Inc. boosted its holdings in Bristol-Myers Squibb by 6.7% during the 2nd quarter. BlackRock Inc. now owns 114,798,394 shares of the biopharmaceutical company’s stock valued at $5,206,108,000 after acquiring an additional 7,178,698 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Bristol-Myers Squibb by 42.7% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 12,749,545 shares of the biopharmaceutical company’s stock valued at $578,192,000 after acquiring an additional 3,816,247 shares during the period. Eaton Vance Management boosted its holdings in Bristol-Myers Squibb by 108.3% during the 2nd quarter. Eaton Vance Management now owns 5,195,648 shares of the biopharmaceutical company’s stock valued at $235,623,000 after acquiring an additional 2,701,008 shares during the period. Finally, Prudential PLC boosted its holdings in Bristol-Myers Squibb by 438.6% during the 2nd quarter. Prudential PLC now owns 2,907,501 shares of the biopharmaceutical company’s stock valued at $130,846,000 after acquiring an additional 2,367,644 shares during the period. 83.02% of the stock is currently owned by hedge funds and other institutional investors.

Shares of BMY stock opened at $66.58 on Thursday. Bristol-Myers Squibb Co has a twelve month low of $42.48 and a twelve month high of $67.09. The stock has a market capitalization of $108.25 billion, a price-to-earnings ratio of 16.73, a P/E/G ratio of 0.85 and a beta of 0.73. The stock has a fifty day simple moving average of $62.52 and a two-hundred day simple moving average of $53.03. The company has a current ratio of 3.83, a quick ratio of 3.72 and a debt-to-equity ratio of 1.37.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The business had revenue of $6.01 billion during the quarter, compared to analysts’ expectations of $5.89 billion. During the same period in the prior year, the business earned $1.09 EPS. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. Research analysts predict that Bristol-Myers Squibb Co will post 4.47 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be issued a $0.45 dividend. This represents a $1.80 annualized dividend and a dividend yield of 2.70%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. The ex-dividend date is Thursday, January 2nd. Bristol-Myers Squibb’s dividend payout ratio is currently 45.23%.

A number of research firms recently issued reports on BMY. William Blair restated a “buy” rating on shares of Bristol-Myers Squibb in a report on Friday, December 13th. Wolfe Research set a $66.00 price objective on Bristol-Myers Squibb and gave the company a “buy” rating in a report on Friday, November 1st. TheStreet upgraded Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a report on Wednesday, September 18th. ValuEngine upgraded Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a report on Tuesday, November 19th. Finally, Argus upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $80.00 price objective for the company in a report on Friday, December 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $61.69.

In related news, SVP John E. Elicker sold 15,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total transaction of $849,900.00. Following the completion of the sale, the senior vice president now directly owns 74,471 shares in the company, valued at approximately $4,219,526.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Louis S. Schmukler sold 25,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total value of $1,414,000.00. Following the sale, the insider now owns 31,963 shares of the company’s stock, valued at $1,807,827.28. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by corporate insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Story: What is the Beige Book?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.